Doing more with less resources used to be a situation common just for academic scientists. This is unfortunately still true for academics but we are seeing others facing many of the same challenges. With the squeeze on budgets and cost cutting resulting from recent worldwide economic challenges, the failure of many drugs to make it through the pipeline to the market, and the increasing costs associated with the drug development process, we are now seeing in the pharmaceutical industry a dramatic shift, perhaps belatedly, to have to accommodate similar challenges of doing more with less.